Navigation Links
Gen-Probe to Webcast Two Upcoming Investor Presentations
Date:10/27/2010

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the Oppenheimer 21st Annual Healthcare Conference in New York on November 2, 2010 at 11:25 a.m. Eastern time, and at the Lazard Capital Markets 7th Annual Healthcare Conference in New York on November 17, 2010 at 10 a.m. Eastern time.  The presentations are scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com. The webcasts will be available for 30 days following the events.

About Gen-ProbeGen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 27 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,300 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our finan
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
2. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
3. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
4. Neogen Acquires Gen-Probes BioKits Food Safety Business
5. Gen-Probe to Webcast Two Upcoming Investor Presentations
6. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
7. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
8. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
9. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
10. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
11. Pharmasset to Webcast an Investor Event from the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Fla. , May 21, 2013  BioRestorative Therapies, ... life sciences company focused on developing stem cell based ... Mark Weinreb , its President and CEO, will ... The conference will be held on Thursday, May ... 109 E 42nd Street in New York City.  Mr. ...
(Date:5/21/2013)... May 21, 2013 Ceregene, Inc. today ... of its double-blind, randomized, controlled Phase 2b clinical ... therapy product designed to deliver the neurotrophic factor ... a more robust response to CERE-120 in Parkinson,s ... relative to those diagnosed 10 years or more ...
(Date:5/21/2013)... STAAR Surgical Company (NASDAQ: STAA ... invasive ophthalmic products, today announced that it will participate ... recent financial results and business developments with investors and ... the 38 th Annual Deutsche Bank 2013 Healthcare ... Westin Waterfront Hotel on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5STAAR Surgical To Present At Upcoming Investor Conferences 2
(Date:5/21/2013)... May 21, 2013 Parker Waichman LLP, a ... injured by defective medical devices, is offering remarks on the ... the Estate of Fred E. Taylor v. Intuitive Surgical, 09-2-03136-5, ... May 21, 2013, Bloomberg report noted that the ... a “car dealership” in how it deployed its strategy to ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... France: One-year results from SOURCE XT one of ... to-date reported today at EuroPCR 2013 show good ... of device success for all access approaches, valve sizes ... followed up 2688 consecutively enrolled patients (mean age 81.5 ... at 93 centres in 17 countries between July 2010 ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... Global Proving Ground (GPG), a fast rising ... retailer of health and fitness supplements, are partnering up ... Island. “We cast the show by having millions ... our unique social networking platform,” states show’s creator James ... an island in the Pacific Ocean, where they must ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
... disparities in cost-effectiveness analysis, would allow policy makers ... reduce disparities between racial ethnic subgroups, and be ... in the Journal of the National ... be used to identify effective and cost-effective strategies ...
... , TUESDAY, Sept. 6 (HealthDay News) -- Breast ... much better response to neoadjuvant chemotherapy -- chemo given ... patients, a new study finds. U.S. researchers looked ... who underwent neoadjuvant chemotherapy. Complete pathological response (pCR) ...
... HealthDay Reporter , TUESDAY, Sept. 6 (HealthDay News) -- ... ibuprofen during the first stage of their pregnancy may ... "We,re seeing a 2.4-fold increased risk in ... said Anick Berard, senior author of a paper published ...
... An innovative approach to treating neonatal feeding problems at ... to feed orally to be discharged earlier and without ... According to American Academy of Pediatrics guidelines, ... the hospital, they must establish safe oral feeding methods. ...
... in German . The stomach bacterium Helicobacter ... development of gastric cancer, the third most common cause of cancer-related ... have now identified a mechanism of Helicobacter pylori that damages the ... for malignant transformation. Gastric cancer is one of the most ...
... been prescribing codeine for postpartum pain management for many years, ... taking the opioid. But the death of an infant ... providers questioning the safety of the drug when used by ... have begun the practice of prescribing oxycodone as an alternative ...
Cached Medicine News:Health News:Modeling disparities may help with cervical cancer prevention 2Health News:Going Straight to Chemo May Be Better for Certain Breast Cancers 2Health News:NSAIDs May Raise Miscarriage Risk: Study 2Health News:NSAIDs May Raise Miscarriage Risk: Study 3Health News:Neonatal and infant feeding disorders program saves infants from lifetime of feeding tubes 2Health News:Stomach bacterium damages human DNA 2Health News:Mother's postpartum oxycodone use: No safer for breastfed infants than codeine 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: